The estimated Net Worth of Roberto Mignone is at least $26.8 Millón dollars as of 18 June 2024. Mr. Mignone owns over 519,000 units of Teva- Pharmaceutical Industries stock worth over $17,618,760 and over the last 7 years he sold TEVA stock worth over $8,838,570. In addition, he makes $339,999 as Independent Director at Teva- Pharmaceutical Industries.
Sign up
Mr. Mignone TEVA stock SEC Form 4 insiders trading
Roberto has made over 9 trades of the Teva- Pharmaceutical Industries stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 519,000 units of TEVA stock worth $8,838,570 on 18 June 2024.
The largest trade he's ever made was buying 750,000 units of Teva- Pharmaceutical Industries stock on 9 May 2018 worth over $14,430,000. On average, Roberto trades about 85,293 units every 140 days since 2018. As of 18 June 2024 he still owns at least 981,000 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Mr. Mignone stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Roberto Mignone biography
Roberto A. Mignone serves as Independent Director of the Company. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, a multi-billion dollar investment management firm founded in 2000 and specializing in long-term equity strategies. Since inception, Bridger Management has focused on the healthcare sector and has developed considerable research expertise in support of its investments. In addition to healthcare, Bridger Management invests in global consumer, technology and financial services companies. Prior to Bridger Management, Mr. Mignone co-founded and served as a partner of Blue Ridge Capital LLC from 1996 to 2000, an investment management firm specialized in health care, technology, media, telecommunications and financial services. Mr. Mignone serves as a trustee and member of the Finance Committee and Nominating Committee of the New York University Langone Medical Center.
What is the salary of Roberto Mignone?
As the Independent Director of Teva- Pharmaceutical Industries, the total compensation of Roberto Mignone at Teva- Pharmaceutical Industries is $339,999. There are 14 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
How old is Roberto Mignone?
Roberto Mignone is 48, he's been the Independent Director of Teva- Pharmaceutical Industries since 2017. There are 25 older and 3 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
What's Roberto Mignone's mailing address?
Roberto's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Insiders trading at Teva- Pharmaceutical Industries
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks y Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
What does Teva- Pharmaceutical Industries do?
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
What does Teva- Pharmaceutical Industries's logo look like?
Complete history of Mr. Mignone stock trades at Teva- Pharmaceutical Industries
Teva- Pharmaceutical Industries executives and stock owners
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:
-
Kaare Schultz,
President, Chief Executive Officer, Director -
Kare Schultz,
Pres, CEO & Director -
Mark Sabag,
Executive Vice President, Chief Human Resources Officer and Global Communications and Brand -
Hafrun Fridriksdottir,
Executive Vice President - Global R&D -
Brendan O'Grady,
Executive Vice President - North America Commercial -
Gianfranco Nazzi,
Executive Vice President - International Markets Commercial -
Dr. Hafrun Fridriksdottir,
Exec. VP of Global R&D -
Gianfranco Nazzi,
Exec. VP of International Markets Commercial -
Eric Drape,
Exec. VP of Global Operations -
Eliyahu Sharon Kalif,
Exec. VP & CFO -
Sol Barer,
Independent Chairman of the Board -
Nechemia Peres,
Independent Director -
Gerald Lieberman,
Independent Director -
Amir Elstein,
Independent Director -
Roberto Mignone,
Independent Director -
Rosemary Crane,
Independent Director -
Jean-Michel Halfon,
Independent Director -
Perry Nisen,
Independent Director -
Ronit Satchi-Fainaro,
Independent Director -
Eliyahu Kalif,
Chief Financial Officer, Executive Vice President -
Kevin Mannix,
Senior Vice President, Investor Relations -
Janet Vergis,
Independent Director -
Abbas Hussain,
Independent Director -
David Stark,
Executive Vice President, Chief Legal Officer -
Eric Drape,
Executive Vice President - Global Operations -
Sven Dethlefs,
Executive Vice President - Global Marketing & Portfolio -
Richard Daniell,
Executive Vice President - European Commercial -
Eli Shani,
Exec. VP of Global Marketing & Portfolio -
Galia Inbar,
Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG -
David M. Stark,
Exec. VP & Chief Legal Officer -
Amir Weiss,
Sr. VP & Chief Accounting Officer -
Lori Queisser,
Sr. VP & Global Compliance Officer -
Andrew J. Weil CPA,
Chief Accounting Officer -
Eric Drapé,
Exec. VP of Global Operations -
Iris Beck Codner,
EVP Global Brand&Communication -
Kare Schultz,
President and CEO -
Michael James Mc Clellan,
EVP, Chief Financial Officer -
Notaristefani Carlo De,
Executive VP Global Operations -
Placid Jover,
See "Remarks" -
Deborah A Griffin,
Chief Accounting Officer -
Varda Shalev,
-
Dan S Suesskind,
Director -
Murray A Goldberg,
Director -
Dov Bergwerk,
Acting Chief Legal Officer -
David R. Mc Avoy,
EVP, Chief Legal Officer -
Andrew Weil,
Chief Accounting Officer -
Galia Inbar,
See "Remarks" -
Eli Shani,
EVP,Global Marketing&Portfolio -
Angus Grant,
EVP, Business Development -
Eric A Hughes,
See "Remarks" -
Vikki L Conway,
See "Remarks" -
Christine Fox,
EVP, Head of U.S. Commercial -
Amir Weiss,
Chief Accounting Officer -
Richard D Francis,
President and CEO -
Matthew Shields,
EVP, Global Operations -
Tal Zvi Zaks,